Center of Isotope: actions for the benefit of public health

Main Article Content

J Cruz Arencibia
R Leyva Montaña
A Perera Pintado
I Hernández González
J Morín Zorrilla

Abstract

To commemorate the 500th anniversary of the city of Havana, the Isotope Center reviews its activity since its creation. The production of radionuclidemarked compounds and other radiochemical work at the Institute of Nuclear Physics, inaugurated in 1969, stimulated the applications of open radioactive sources, which can be considered as the most tangible organized antecedent of the center. Later in the 1980s, the Executive Secretary for Nuclear Affairs accelerated, diversified and expanded nuclear applications, developed the training of highly qualified staff and experts as well as international cooperation. The creation of the Center for Applied Nuclear Development Studies coincided with the consolidation of a group of biotechnological research and production institutions and with these applications gaining importance in Nuclear Medicine. It was soon recognized that it was not possible to continue managing a growing inventory of radionuclides. As a result, CENTIS, a specialized center with a complete cycle, was designed and built, which comprised not only research and development, but also production and marketing. When in 1994 CENTIS became part of the Nuclear Energy Agency, investment was concluded and the production methodologies of the most important radiopharmaceuticals were established. In more than 20 years of work CENTIS has become the main support of Nuclear Medicine in the country. With its metrological capabilities in the magnitude of radioactivity and its non-clinical and clinical research, it is increasingly part of the socio-economic life of the country and its capital. In this paper the main results of each stage are detailed in relation to the mission of the center and a technical assessment is made regarding the actions taken to favor their target sectors: health and biomedical research. Periods of five years in favor of centuries.

Article Details

How to Cite
Cruz Arencibia, J., Leyva Montaña, R., Perera Pintado, A., Hernández González, I., & Morín Zorrilla, J. (2019). Center of Isotope: actions for the benefit of public health. Nucleus, (66), 32-38. Retrieved from http://nucleus.cubaenergia.cu/index.php/nucleus/article/view/688
Section
Panorama Nuclear

References

[1]. Centro de Producción y Desarrollo de Compuestos Marcados y Radiofármacos. Tarea de proyección. SEAN, UPCIN, 1988.
[2]. MORÍN ZORRILLA J, OLIVÉ ÁLVAREZ E. Avances y proyecciones de la radioquímica y de las técnicas analíticas nucleares. Nucleus. 1989; (7): 31-36.
[3]. MORÍN ZORRILLA J, OLIVÉ ÁLVAREZ E, ISAAC TEJERA M, CRUZ ARENCIBIA J. Control físico-químico de calidad del 131I-2-yodohipurato sódico. Nucleus. 1992; (12): 19-21.
[4]. ABDALA JIMÉNEZ L, HERNÁNDEZ GONZÁLEZ I, OLIVÉ ÁLVAREZ E, CRUZ ARENCIBIA J. Nuevo kit para la preparación de 99mTc-MAG3”. Nucleus . 1993; (15): 23-26.
[5]. CRUZ ARENCIBIA J, LÓPEZ RODRÍGUEZ M, HERNÁNDEZ GONZÁLEZ I. Método rápido para la determinación de pureza radioquímica del tecnecio 99m-Tc MIBI. Nucleus . 1995; (18): 17-20.
[6]. Examen de la tecnología nuclear 2006. Informe del Director General. GC (50)/INF/3. Fecha: 7 de julio de 2006.
[7]. International Atomic Energy Agency (IAEA). Technetium-99 radiopharmaceuticals: manufacture of Kits. Technical Reports Series No.466. Vienna: IAEA, 2008,
[8]. MORÍN ZORRILLA J, CRUZ ARENCIBIA J. Radiofármacos de Galio- 68. Nucleus . 2012; (51): 1-5.
[9]. PÉREZ PIJUÁN S. Centro de Isótopos: continuidad, presencia y proyecciones en su Aniversario 15. Nucleus . 2012; (52): 3-8.
[10]. LEYVA R, PERERA A, MORÍN J. Radiofármacos en inmunocentelleografía y Radioinmunoterapia”. Nucleus . 2012, (52): 68-72.
[11]. ALBERTI RAMÍREZ A, CRUZ MORALES A, MORÍN ZORRILLA J. Itrio-90 como radionúclido para terapia. Nucleus 2012; (52): 62-67.
[12]. HERNÁNDEZ I. Investigaciones no clínicas en el Centro de Isótopos en función de la industria farmacéutica y biotecnológica”. Nucleus . 2012; (52): 35-41.
[13]. Expediente del Resultado Fosfato de Fosfato de Cromo (III)-32P de CENTIS en el tratamiento de la sinovitis crónica. AENTA, 2013.
[14]. CRUZ ARENCIBIA J. La producción de radiofármacos en CENTIS. Nucleus . 2014; (56): 27-32.
[15]. PEÑA Y, PERERA A, BATISTA JF. Immunoscintigraphy and Radioimmunotherapy in Cuba: Experiences with Labeled Monoclonal Antibodies for Cancer Diagnosis and Treatment (1993-2013). MEDICC Review. 2014; 16: 55-60.
[16]. PEÑA Y, HERNANDEZ P, BATISTA JF, PERERA A, COCA MA. Lymphoscintigraphy for the assessment of autologous stem cell implantation for chronic lymphedema. Clin Nucl Med. 2015; 40: 217-219.
[17]. PEÑA Y, CROMBET T, BATISTA JF, PRATS A, PERERA A. Immunoscintigraphy with 99mTc-Nimotuzumab for planning immunotherapy in patients with bone metastases due to prostate cancer. Clin Nucl Med . 2016; 41(3): 244-246.
[18]. CRUZ ARENCIBIA J, TAYLOR DELGADO T, MORÍN ZORRILLA J. Posibilidades del mercado de radiofármacos. Escenario cubano. Nucleus . 2017; (62): 25-29.
[19]. CRUZ ARENCIBIA J, ROJO MARTÍNEZ C, FIRVIDA LAMELAS R. Estudio de factibilidad “Recapitalización tecnológica de CENTIS”. 2017.
[20]. PEÑA Y, CROMBET T, BATISTA JF, TORRES LA, VERGARA A, PERERA A. Immunoscintigraphy with 99mTc-Nimotuzumab in Patients with Non-Small Cell Lung Cancer that will Receive Therapy with the Monoclonal Antibody. Ann Clin Case Rep. 2017; 2: 1354.
[21]. Centro de Isótopos (CENTIS). Balance anual de trabajo. CENTIS, 2018.

Most read articles by the same author(s)